Morten Ladekarl

Aalborg University

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (19)

Jakob Kirkegård

Aarhus University Hospital

DENMARK

View details

Anna Sundlöv

Lund University

SWEDEN

View details

Martin Bøgsted

Professor

Aalborg University

DENMARK

View details

Peter Meldgaard

Assistant Professor

Aarhus University

DENMARK

View details

Lise Ventzel

MD PhD Associate Professor

Herlev Hospital

DENMARK

View details

Karen Dybkaer

Aalborg University

DENMARK

View details

Julia Johansen

Professor

Copenhagen University Hospital

DENMARK

View details

Lars Henrik Jensen

DENMARK

View details

Annette Raskov Kodahl

Odense University Hospital

DENMARK

View details

Heidi Søgaard Christensen

Aalborg University

DENMARK

View details

Inge Søkilde Pedersen

Aalborg University

DENMARK

View details

Birgitte Bjørnhart

Odense University Hospital

DENMARK

View details

Christopher Aboo

Aalborg University

DENMARK

View details

Halla Skuladottir

Clinical Associate Professor

Aarhus University

DENMARK

View details

Emil Kofod-Olsen

Aalborg University

DENMARK

View details

Andreas Carus

Aalborg University

DENMARK

View details

Sidsel Christy Lindgaard

Københavns Universitet

DENMARK

View details

Seppo W. Langer

DENMARK

View details

Per Pfeiffer

Odense University Hospital

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Morten Ladekarl

Research Interests

Contact this professor

Articles (26)

The prognostic impact of early ctDNA kinetics in metastatic pancreatic cancer using the ctDNA Response Evaluation Criteria in Solid Tumors (ctDNA-RECIST)

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Longer survival with precision medicine in late-stage cancer patients

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Identification and validation of a ferroptosis-related long non-coding RNA signature as a prognostic biomarker for hepatocellular carcinoma

ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel

Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma

Twenty-one-year report from the Danish Health Authority Expert Advisory Panel for review of treatment of 10 000 cancer patients

PANTAX

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial

Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial

Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation

Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation

Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients

Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital

Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms

Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

ProTarget

Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?

Prognostic significance of T-cell–inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer

Collaborators (19)

Jakob Kirkegård

Anna Sundlöv

Martin Bøgsted

Peter Meldgaard

Lise Ventzel

Karen Dybkaer

Julia Johansen

Lars Henrik Jensen

Annette Raskov Kodahl

Heidi Søgaard Christensen

Inge Søkilde Pedersen

Birgitte Bjørnhart

Christopher Aboo

Halla Skuladottir

Emil Kofod-Olsen

Andreas Carus

Sidsel Christy Lindgaard

Seppo W. Langer

Per Pfeiffer

Make your next move.